Wave’s challenge to Sarepta in Duchenne falls flat

The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

Solid Bio falls as FDA halts DMD trial over safety concerns

In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been  filed with the FDA for the treatment of DMD.

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year. Japanese pharma Nippon Shinyaku (NS Pharma) has announced its candidate for Duchenne musuclar dystrophy (DMD) has been submitted to the FDA

Biosimilar Remicade reaches market in Japan and India

India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

1 2 3 4 [ Next 5 results ]